The content you are trying to access has moved to Revvity.com. Explore, discover (and in certain contries, buy) our products and services on our new website. Click to visit now or you will be automatically redirected.
Over the last decade, chimeric antigen receptor (CAR) T-cell therapies have attracted growing interest for their potential to treat a wide range of cancers. To date, six CAR T-cell therapies have been approved by the FDA, all for the treatment of hematological malignancies such as leukemia and lymphoma.
In contrast to the success of CAR T-cell therapies in liquid cancers, development for the treatment of solid tumors, including glioblastoma, has progressed at a much slower pace. This is due to several factors, including the challenge of identifying tumor-specific antigens due to tumor heterogeneity, the impact of the tumor immunosuppressive microenvironment on CAR T-cell activity, and the limited ability to infiltrate tumor tissue.
Highly expressed tumor-associated antigens (TAAs) are often the target of CAR-T cells, but solid tumors display antigen heterogeneity between tumor types and at different stages of disease. This increases the likelihood of antigen escape and tumor recurrence. Off-tumor toxicity can also be an issue if TAAs are expressed in normal tissues.
In addition, most solid tumors are embedded in a hostile, immunosuppressive microenvironment infiltrated by numerous cell types and excessive blood vessels. This can hinder the effector function of CAR-T cells and inhibit their clinical efficacy.
To overcome these challenges, researchers have explored multi-targeting or tandem CAR strategies using viral vector or non-viral transposon-transposase-based systems. While these approaches enable long-term expression, they have limitations such as limited transgene capacity, lengthy manufacturing processes, and the risk for off-tumor toxicities.
mRNA-based Multifunctional CAR T-cells
CAR-T cells engineered with mRNA encoding the CAR potentially offer a safer alternative to those transduced with viral vectors. The transient nature and high transfection efficiency of mRNA-based modifications allow for the generation of multifunctional T cells that express both the CAR and proinflammatory cytokines.
In a recent study, Meister et al. developed multi-targeting mRNA-based CAR T-cells that demonstrated promising anti-glioma activity in vitro and in vivo.1 They used a CAR based on the natural killer group 2D (NKG2D) receptor and co-electroporated mRNA encoding for the pro-inflammatory cytokines IL12 and IFNα2 into T cells.
Using high-content screening and fluorescence molecular tomography, the researchers found that these multifunctional CAR-T cells had the strongest anti-glioma activity in both glioblastoma mouse models and patient samples compared to T cells expressing just the CAR or cytokines alone. The team notes that the limitation of the mRNA-based T-cell modifications is the transient nature, which is advantageous in the case of off-tumor toxicities but would require repeated administrations. However, they conclude that their approach could be a promising treatment strategy for patients with glioblastoma.
Download this publication review to learn how the researchers have evaluated the efficiency of mRNA-based multifunctional CAR T-cells against glioblastoma in vitro and in vivo.
Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clinical Cancer Research. 2022 Nov 1;28(21):4747–56.